StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

Polaryx Therapeutics cash

Cash and short-term investments held at the end of each period.

Polaryx Therapeutics's cash was $8.44M at Sep 30, 2026. For fiscal 2025 it was $5.14M, up 11.3% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.14M+11.3%
FY2024Dec 31, 2024$4.62M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$8.44M+82.6%
Q2 FY2026Jun 30, 2026$11.54M–
Q1 FY2026Mar 31, 2026$3.08M–
Q4 FY2025Dec 31, 2025$5.14M–
Q4 FY2024Dec 31, 2024$4.62M–

More Polaryx Therapeutics figures

See a number that looks wrong?